3rd Quarter - Report

ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP

Firm
Client
Income
—
Expenses
$880,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Intellectual property and issues in China and potential impact on US entities

LobbyistCovered position, as disclosed
BRADLEY ALLEN ROSSIN —

Contacted: Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); SENATE; State, Dept of (DOS)

Taxation/Internal Revenue Code TAX

HR 4679 Stop Corporate Inversions Act of 2014, S 2360 Stop Corporate Inversions Act of 2014 (in the context of corporate acquisition activity)

LobbyistCovered position, as disclosed
JACQUELINE POMFRET KIRBY —
JOHN MYERS —
BRADLEY ALLEN ROSSIN —
BELA SASTRY —

Contacted: State, Dept of (DOS); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; Patent & Trademark Office (PTO); Commerce, Dept of (DOC)

Bills named: H.R. 4679 (113th)

Copyright/Patent/Trademark CPT

HR 3116 (MODDERN Cures Act) issues related to data exclusivity and patent rights for dormant therapies

LobbyistCovered position, as disclosed
THERESA JOLIVETTE —
JACQUELINE POMFRET KIRBY —

Contacted: Patent & Trademark Office (PTO); SENATE; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); State, Dept of (DOS)

Bills named: H.R. 3116 (113th)

Health Issues HCR

Issues related to 21st Century Cures legislation and role of incentives in advancement of treatments and cures HR 3116 (MODDERN Cures Act) issues related to data exclusivity and patent rights for dormant therapies Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing programIssues related to pediatric medication access and impact of public guidelines on access Issues related to FDA and Biomedical Advanced Research Development Authority appropriations (no bill number) Medication adherence related legislation (no bill number) Issues related to oncology legislation, including medication affordability Issues related to opiod use, diversion and DEA scheduling (no legislation) Issues related to transition of care from different care sites (no legislation) Issues related to drug safety and supply chain protections, including e-labeling (no bill number)

LobbyistCovered position, as disclosed
MARIA FIRVIDA —
CARRIE HARNEY —
THERESA JOLIVETTE —
JACQUELINE POMFRET KIRBY —
JOHN MYERS —
BELA SASTRY —

Contacted: State, Dept of (DOS); HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); Commerce, Dept of (DOC)

Bills named: H.R. 3116 (113th)

Medicare/Medicaid MMM

H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid program awareness, including discussions on potential changes to program strucutre Issues related to transition of care from different care sites (no legislation)

LobbyistCovered position, as disclosed
MARIA FIRVIDA —
JACQUELINE POMFRET KIRBY —
JOHN MYERS —
BELA SASTRY —

Contacted: SENATE; Patent & Trademark Office (PTO); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); State, Dept of (DOS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 3590 (113th)

Consumer Issues/Safety/Products CSP

Issues related to drug safety and supply chain protections, including e-labeling (no bill number)

LobbyistCovered position, as disclosed
THERESA JOLIVETTE —
JACQUELINE POMFRET KIRBY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Commerce, Dept of (DOC); State, Dept of (DOS); U.S. Trade Representative (USTR)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.